Prolonged administration of temozolomide in adult patients with anaplastic glioma

Anticancer Research

Volumn 31, Issue 11, 2011, Pages 3873-3877

  Freyschlag, C F ^a   Smolczyk, D R ^b   Janzen, E ^b   Schmieder, K ^b   Thome C ^a   Lohr, F ^b   Wenz, F ^b   Weiss, C ^b   Tuettenberg, J ^c   Seiz Rosenhagen, Marcel ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c SHG Klinikum Idar Oberstein   (Germany)

Author keywords

Anaplastic gliomas; Long term administration; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; AGED; ANAPLASTIC GLIOMA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; GLIOMA; HUMAN; LONG TERM CARE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CARCINOMA; DACARBAZINE; DISEASE PROGRESSION; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 83055167285     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Donahue B, Scott CB, Nelson JS, Rotman M, Murray KJ, Nelson DF, Banker FL, Earle JD, Fischbach JA, Asbell SO, Gaspar LE, Markoe AM and Curran W: Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02. Int J Radiat Oncol Biol Phys 5: 911-914, 1997. (Pubitemid 27353668)
2. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D and Gorlia T: Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 18: 2715-2722, 2006. (Pubitemid 46630567)
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 10: 987-996, 2005. (Pubitemid 40349501)
4. Hau P, Koch D, Hundsberger T, Marg E, Bauer B, Rudolph R, Rauch M, Brenner A, Rieckmann P, Schuth J, Jauch T, Koch H and Bogdahn U: Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology 9: 688-690, 2007. (Pubitemid 46667817)
5. Seiz M, Krafft U, Freyschlag CF, Weiss C, Schmieder K, Lohr F, Wenz F, Thomé C and Tuettenberg J: Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution. Journal of Cancer Research and Clinical Oncology 136: 1691-1695, 2010.
6. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 3: 176-181, 2003. (Pubitemid 36962641)
7. Macdonald DR, Cascino TL, Schold SCJ and Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 7: 1277-1280, 1990. (Pubitemid 20195640)
8. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S and Levin VA: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 9: 2762-2771, 1999. (Pubitemid 29415233)
9. Surawicz TS, Davis F, Freels S, Laws ERJ and Menck HR: Brain tumor survival: results from the National Cancer Data Base. J Neurooncol 2: 151-160, 1998. (Pubitemid 29010168)
10. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A and Weller M: NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 35: 5874-5880, 2009.
11. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F and Reulen HJ: Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 5: 392-401, 2006.
12. Khasraw M, Bell D and Wheeler H: Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? J Clin Neurosci 6: 854-855, 2009.